Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.

Abstract

The treatment of advanced prostate cancer (PCa) remains a challenge. Identification of new molecular mechanisms that regulate PCa initiation and progression would provide targets for the development of new cancer treatments. The Foxm1 transcription factor is highly up-regulated in tumor cells, inflammatory cells, and cells of tumor microenvironment. However, its functions in different cell populations of PCa lesions are unknown. To determine the role of Foxm1 in tumor cells during PCa development, we generated two novel transgenic mouse models, one exhibiting Foxm1 gain-of-function and one exhibiting Foxm1 loss-of-function under control of the prostate epithelial-specific Probasin promoter. In the transgenic adenocarcinoma mouse prostate (TRAMP) model of PCa that uses SV40 large T antigen to induce PCa, loss of Foxm1 decreased tumor growth and metastasis. Decreased prostate tumorigenesis was associated with a decrease in tumor cell proliferation and the down-regulation of genes critical for cell proliferation and tumor metastasis, including Cdc25b, Cyclin B1, Plk-1, Lox, and Versican. In addition, tumor-associated angiogenesis was decreased, coinciding with reduced Vegf-A expression. The mRNA and protein levels of 11β-Hsd2, an enzyme playing an important role in tumor cell proliferation, were down-regulated in Foxm1-deficient PCa tumors in vivo and in Foxm1-depleted TRAMP C2 cells in vitro. Foxm1 bound to, and increased transcriptional activity of, the mouse 11β-Hsd2 promoter through the -892/-879 region, indicating that 11β-Hsd2 was a direct transcriptional target of Foxm1. Without TRAMP, overexpression of Foxm1 either alone or in combination with inhibition of a p19(ARF) tumor suppressor caused a robust epithelial hyperplasia, but was insufficient to induce progression from hyperplasia to PCa. Foxm1 expression in prostate epithelial cells is critical for prostate carcinogenesis, suggesting that inhibition of Foxm1 is a promising therapeutic approach for prostate cancer chemotherapy.

• Authors: Yuqi Cai, David Balli, Vladimir Ustiyan, Logan Fulford, Andrea Hiller, Vinko Misetic, Yufang Zhang, Andrew M Paluch, Susan E Waltz, Susan Kasper, Tanya V Kalin
• Journal: The Journal of biological chemistry (J Biol Chem) Vol. 288 Issue 31 Pg. 22527-41 (Aug 02 2013) ISSN: 1083-351X [Electronic] United States
• PMID: 23775078 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• DNA Primers
• FOXM1 protein, human
• Forkhead Box Protein M1
• Forkhead Transcription Factors

Topics

• Base Sequence
• Cell Transformation, Neoplastic
• DNA Primers
• Epithelial Cells (metabolism)
• Forkhead Box Protein M1
• Forkhead Transcription Factors (metabolism)
• Humans
• Male
• Prostate (cytology, metabolism)
• Prostatic Neoplasms (metabolism, pathology)
• Real-Time Polymerase Chain Reaction